Which has preferable earnings & valuation, COGT or MBX?

Cogent Biosciences is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A MBX Biosciences N/A N/A -$86.97M -$2.21 N/A

Is COGT or MBX more profitable?

MBX Biosciences' return on equity of -24.52% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% MBX Biosciences N/A -24.52% -23.59%

Does the media refer more to COGT or MBX?

In the previous week, Cogent Biosciences had 5 more articles in the media than MBX Biosciences. MarketBeat recorded 7 mentions for Cogent Biosciences and 2 mentions for MBX Biosciences. Cogent Biosciences' average media sentiment score of 0.48 beat MBX Biosciences' score of 0.47 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CNTA or MBX more profitable?

MBX Biosciences' return on equity of -24.52% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Centessa Pharmaceuticals N/A -60.37% -44.17% MBX Biosciences N/A -24.52% -23.59%

Does the media prefer CNTA or MBX?

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 2 mentions for MBX Biosciences. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat MBX Biosciences' score of 0.47 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, SRRK or MBX?

MBX Biosciences is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.59 N/A MBX Biosciences N/A N/A -$86.97M -$2.21 N/A

Is SRRK or MBX more profitable?

MBX Biosciences' return on equity of -24.52% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% MBX Biosciences N/A -24.52% -23.59%

Does the media favor TGTX or MBX?

In the previous week, TG Therapeutics had 11 more articles in the media than MBX Biosciences. MarketBeat recorded 13 mentions for TG Therapeutics and 2 mentions for MBX Biosciences. TG Therapeutics' average media sentiment score of 0.74 beat MBX Biosciences' score of 0.47 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, MBX or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.21 N/A Belite Bio N/A N/A -$77.61M -$2.53 N/A

Is MBX or BLTE more profitable?

Belite Bio's return on equity of -13.14% beat MBX Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -24.52% -23.59% Belite Bio N/A -13.14% -12.88%

Does the media prefer MBX or BLTE?

In the previous week, Belite Bio had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 4 mentions for Belite Bio and 2 mentions for MBX Biosciences. Belite Bio's average media sentiment score of 0.49 beat MBX Biosciences' score of 0.47 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MBX Biosciences (MBX) Competitors

$30.05 -0.65 (-2.12%)

Closing price 04:00 PM Eastern

Extended Trading

$30.04 0.00 (-0.02%)

As of 04:35 PM Eastern

Compare

MBX vs. COGT, CNTA, SRRK, TGTX, and BLTE

Should you buy MBX Biosciences stock or one of its competitors? MarketBeat compares MBX Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MBX Biosciences include Cogent Biosciences (COGT), Centessa Pharmaceuticals (CNTA), Scholar Rock (SRRK), TG Therapeutics (TGTX), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

How does MBX Biosciences compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and MBX Biosciences (NASDAQ:MBX) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Cogent Biosciences presently has a consensus target price of $43.73, suggesting a potential upside of 35.55%. MBX Biosciences has a consensus target price of $60.22, suggesting a potential upside of 100.41%. Given MBX Biosciences' higher possible upside, analysts plainly believe MBX Biosciences is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Cogent Biosciences is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

MBX Biosciences' return on equity of -24.52% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
MBX Biosciences	N/A	-24.52%	-23.59%

In the previous week, Cogent Biosciences had 5 more articles in the media than MBX Biosciences. MarketBeat recorded 7 mentions for Cogent Biosciences and 2 mentions for MBX Biosciences. Cogent Biosciences' average media sentiment score of 0.48 beat MBX Biosciences' score of 0.47 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MBX Biosciences beats Cogent Biosciences on 6 of the 11 factors compared between the two stocks.

How does MBX Biosciences compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and MBX Biosciences (NASDAQ:MBX) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Centessa Pharmaceuticals currently has a consensus target price of $41.33, suggesting a potential upside of 3.72%. MBX Biosciences has a consensus target price of $60.22, suggesting a potential upside of 100.41%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe MBX Biosciences is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Centessa Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

MBX Biosciences has lower revenue, but higher earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	396.45	-$197.53M	-$1.79	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 4 mentions for Centessa Pharmaceuticals and 2 mentions for MBX Biosciences. Centessa Pharmaceuticals' average media sentiment score of 1.33 beat MBX Biosciences' score of 0.47 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MBX Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MBX Biosciences' return on equity of -24.52% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
MBX Biosciences	N/A	-24.52%	-23.59%

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 52.2% of MBX Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

MBX Biosciences beats Centessa Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does MBX Biosciences compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and MBX Biosciences (NASDAQ:MBX) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Scholar Rock has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Scholar Rock presently has a consensus target price of $56.00, indicating a potential upside of 25.45%. MBX Biosciences has a consensus target price of $60.22, indicating a potential upside of 100.41%. Given MBX Biosciences' higher probable upside, analysts plainly believe MBX Biosciences is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

91.1% of Scholar Rock shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by company insiders. Comparatively, 52.2% of MBX Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, MBX Biosciences had 1 more articles in the media than Scholar Rock. MarketBeat recorded 2 mentions for MBX Biosciences and 1 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.87 beat MBX Biosciences' score of 0.47 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Overall Sentiment
Scholar Rock	Very Positive
MBX Biosciences	Neutral

MBX Biosciences is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

MBX Biosciences' return on equity of -24.52% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
MBX Biosciences	N/A	-24.52%	-23.59%

Summary

MBX Biosciences beats Scholar Rock on 8 of the 13 factors compared between the two stocks.

How does MBX Biosciences compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and MBX Biosciences (NASDAQ:MBX) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

TG Therapeutics presently has a consensus price target of $52.50, suggesting a potential upside of 30.89%. MBX Biosciences has a consensus price target of $60.22, suggesting a potential upside of 100.41%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe MBX Biosciences is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, TG Therapeutics had 11 more articles in the media than MBX Biosciences. MarketBeat recorded 13 mentions for TG Therapeutics and 2 mentions for MBX Biosciences. TG Therapeutics' average media sentiment score of 0.74 beat MBX Biosciences' score of 0.47 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
MBX Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TG Therapeutics has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	9.96	$447.18M	$2.86	14.02
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

TG Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to MBX Biosciences' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
MBX Biosciences	N/A	-24.52%	-23.59%

58.6% of TG Therapeutics shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Comparatively, 52.2% of MBX Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

TG Therapeutics beats MBX Biosciences on 10 of the 14 factors compared between the two stocks.

How does MBX Biosciences compare to Belite Bio?

MBX Biosciences (NASDAQ:MBX) and Belite Bio (NASDAQ:BLTE) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

MBX Biosciences presently has a consensus target price of $60.22, indicating a potential upside of 100.41%. Belite Bio has a consensus target price of $203.00, indicating a potential upside of 47.93%. Given MBX Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe MBX Biosciences is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Belite Bio had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 4 mentions for Belite Bio and 2 mentions for MBX Biosciences. Belite Bio's average media sentiment score of 0.49 beat MBX Biosciences' score of 0.47 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.5% of Belite Bio shares are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Belite Bio is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

MBX Biosciences has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market.

Belite Bio's return on equity of -13.14% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Belite Bio	N/A	-13.14%	-12.88%

Summary

MBX Biosciences beats Belite Bio on 7 of the 13 factors compared between the two stocks.

Get MBX Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBX vs. The Competition

Export

Metric	MBX Biosciences	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.46B	$928.81M	$4.28B	$12.42B
Dividend Yield	N/A	4.84%	7.92%	5.29%
P/E Ratio	N/A	1.45	21.82	24.19
Price / Sales	N/A	121.23	131.62	138.36
Price / Cash	N/A	20.06	56.86	57.88
Price / Book	3.66	8.15	32.78	6.72
Net Income	-$86.97M	-$3.91M	$109.80M	$337.19M
7 Day Performance	-5.74%	-0.36%	-0.20%	0.48%
1 Month Performance	0.91%	67.21%	3.93%	5.07%
1 Year Performance	N/A	98.64%	16.15%	34.25%

MBX Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBX MBX Biosciences	2.9143 of 5 stars	$30.05 -2.1%	$60.22 +100.4%	N/A	$1.46B	N/A	N/A	N/A
COGT Cogent Biosciences	3.1612 of 5 stars	$34.96 -1.2%	$43.73 +25.1%	+484.0%	$5.97B	N/A	N/A	80
CNTA Centessa Pharmaceuticals	2.1382 of 5 stars	$39.76 -0.1%	$41.33 +4.0%	+197.5%	$5.93B	$15M	N/A	200	Positive News
SRRK Scholar Rock	3.3262 of 5 stars	$49.30 -1.0%	$56.00 +13.6%	+50.1%	$5.91B	N/A	N/A	140	Positive News
TGTX TG Therapeutics	3.8957 of 5 stars	$37.94 -2.3%	$52.50 +38.4%	+2.5%	$5.81B	$616.29M	13.27	290	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MBX Biosciences (MBX) Competitors

MBX vs. COGT, CNTA, SRRK, TGTX, and BLTE

How does MBX Biosciences compare to Cogent Biosciences?

Summary

How does MBX Biosciences compare to Centessa Pharmaceuticals?

Summary

How does MBX Biosciences compare to Scholar Rock?

Summary

How does MBX Biosciences compare to TG Therapeutics?

Summary

How does MBX Biosciences compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX vs. The Competition

MBX Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MBX Biosciences (MBX) Competitors

MBX vs. COGT, CNTA, SRRK, TGTX, and BLTE

How does MBX Biosciences compare to Cogent Biosciences?

Do analysts prefer COGT or MBX?

Which has preferable earnings & valuation, COGT or MBX?

Which has more risk & volatility, COGT or MBX?

Is COGT or MBX more profitable?

Does the media refer more to COGT or MBX?

Summary

How does MBX Biosciences compare to Centessa Pharmaceuticals?

Do analysts rate CNTA or MBX?

Which has more volatility & risk, CNTA or MBX?

Which has stronger valuation and earnings, CNTA or MBX?

Does the media prefer CNTA or MBX?

Is CNTA or MBX more profitable?

Do institutionals and insiders hold more shares of CNTA or MBX?

Summary

How does MBX Biosciences compare to Scholar Rock?

Which has more volatility & risk, SRRK or MBX?

Do analysts prefer SRRK or MBX?

Do institutionals & insiders believe in SRRK or MBX?

Does the media favor SRRK or MBX?

Which has better earnings and valuation, SRRK or MBX?

Is SRRK or MBX more profitable?

Summary

How does MBX Biosciences compare to TG Therapeutics?

Do analysts rate TGTX or MBX?

Does the media favor TGTX or MBX?

Which has higher valuation & earnings, TGTX or MBX?

Which has more volatility & risk, TGTX or MBX?

Is TGTX or MBX more profitable?

Do institutionals and insiders hold more shares of TGTX or MBX?

Summary

How does MBX Biosciences compare to Belite Bio?

Do analysts prefer MBX or BLTE?

Does the media prefer MBX or BLTE?

Do institutionals and insiders believe in MBX or BLTE?

Which has better valuation & earnings, MBX or BLTE?

Which has more risk and volatility, MBX or BLTE?

Is MBX or BLTE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX vs. The Competition

MBX Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools